Anti-Aging

NAD+

Nicotinamide Adenine Dinucleotide · NAD

Cofactor, not a peptide. IV/SubQ NAD+ is a clinic product. Plasma NAD after an infusion is not a sirtuin longevity NDA. NR/NMN are different exposures.

Not FDA-approved - research chemical

Reviewed by CalcMyPeptide Editorial Team

·Last updated: August 2026·Evidence: Low·3 peer-reviewed citations

Typical research dose

50-250 mg (SubQ) or 250-1000 mg (IV)

Frequency

1-3× weekly

Half-life

Rapidly incorporated intracellularly; serum half-life <1 hour

Common vials

100 mg / 500 mg

CAS

53-84-9

Molecular weight

663.43 g/mol

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

Longevity / aging2.5/10
NAD biology is textbook. Exogenous IV/SubQ NAD+ as an anti-aging drug is a clinic product, not a sirtuin RCT. Mechanism band plus wellness-clinic haircut.

Compound card

Class: Cofactor (NAD+), not a peptide
Formula: C21H27N7O14P2
Status: Not FDA-approved · research use

Dose it

100 mg + 2 mL BAC water → 50 mg/mL · 50000 mcg ≈ 100 units (U-100)

Open in calculator

How it works

NAD+ (Nicotinamide Adenine Dinucleotide) is a foundational coenzyme ubiquitous in every living cell, acting as the critical hydrogen and electron carrier in cellular respiration and redox reactions. Within the mitochondria, it cycles between its oxidized (NAD+) and reduced (NADH) states to facilitate the transfer of high-energy electrons through Complexes I and III of the electron transport chain, directly driving the oxidative phosphorylation that generates ATP.

Beyond basic energy metabolism, NAD+ operates as an essential, expendable substrate for critical longevity and regulatory enzymes. It is required for the activation of **sirtuins (SIRT1-7)**, a family of protein deacetylases that govern gene silencing, circadian rhythm, cellular stress resistance, and apoptosis. Furthermore, NAD+ is consumed by **PARPs (Poly ADP-Ribose Polymerases)** during DNA damage repair, and by **CD38** signaling proteins involved in calcium mobilization and immune response.

Because maintaining optimal NAD+ levels is metabolically expensive, concentrations naturally decline by up to 50% between the ages of 40 and 60. This systemic depletion severely impairs mitochondrial efficiency, diminishes DNA repair capacity, and downregulates sirtuin activity - all of which are fundamental drivers of biological aging and degenerative disease. While oral precursors (like NMN and NR) must navigate the salvage pathway to be converted step-wise into the active molecule, direct SubQ or IV administration of NAD+ immediately replenishes the intracellular pool, forcing rapid activation of these vital repair mechanisms.

Source: PMID: 29514064

Buffered vs. Unbuffered NAD+

When purchasing NAD+ for injection, you will often encounter "buffered" and "unbuffered" options. This distinction is entirely about injection comfort, not biological effectiveness. The biological molecule is identical.

Unbuffered NAD+ is the mainstream, standard form used by researchers. Because it is the pure, raw element, it has a naturally low, highly acidic pH in solution (around 3.0-4.0). When injected subcutaneously, this acidity causes a notorious sensory effect - often described as an intense stinging or burning at the injection site that can last a few minutes. However, it is the most affordable and widely available version.

Buffered NAD+ includes a pre-mixed alkalinizing agent (typically a mild sodium bicarbonate solution) in the reconstitution solvent. This raises the pH closer to neutral physiological levels (pH 7.4), significantly reducing or entirely eliminating the infamous "NAD burn". It is usually sold as a premium kit for individuals highly sensitive to injection site pain.

Background & History

NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme found in all living cells, central to energy metabolism and DNA repair via sirtuins and PARP enzymes. While not a peptide, it is frequently categorized alongside injectable therapeutic compounds. Its role in aging was established by David Sinclair at Harvard (2013, Cell), demonstrating NAD+ decline drives mitochondrial dysfunction and that restoration reverses aging hallmarks in mice. NAD+ IV therapy and NMN precursors have become the most widely used longevity interventions in anti-aging medicine.

Research Use Cases

✓Identity: cofactor vs peptide vs NR/NMN
✓IV clinic product is not a sirtuin NDA
✓Not a neurodegeneration or addiction protocol on this site

Dosing

Phase	Dose	Frequency	Notes
SubQ Protocol	50 - 100 mg	Daily (SC) or 3-5x per week	Subcutaneous is convenient for regular maintenance dosing. May cause injection site irritation at higher doses.
IV Infusion	250 - 1000 mg	1-3x per week (slow IV infusion)	Clinic-administered over 1-4 hours. Infuse slowly to avoid nausea and chest tightness. Higher bioavailability than SubQ.

Administration

Route / form

Subcutaneous injection or intravenous infusion

Timing

Morning preferred. No fasting required.

Empty stomach?

No - Food timing is not critical.

Timeline

Day 1-3 (IV)

Rapid energy boost, improved mental clarity. Nausea possible with first infusions - infuse slowly.

Week 2-4 (SubQ)

Improved mitochondrial energy production. Enhanced recovery from exercise.

Month 1-3

Sirtuin activation. DNA repair capacity improvement. Gradual anti-aging metabolic benefits.

Who it is for

Cellular Energy / Mitochondrial Health

High

Direct precursor to ATP production. Bypasses the conversion steps required by NMN/NR oral supplements.

Longevity / DNA Repair

Moderate

Activates sirtuins and PARP-mediated DNA repair. Declining NAD+ is a key mechanism of aging.

Reconstitution

Vial	Water	Concentration	Example dose
100 mg lyophilized	2 mL BAC	50 mg/mL	Clinic IV is not this calculator. SubQ 100 mg vial math: 100 mg / 2 mL = 50 mg/mL.

Change vial size or water volume? Open the reconstitution calculator.

Safety & Considerations

Essential human coenzyme. IV administration may cause nausea and chest tightness if infused too rapidly - always infuse over 1-4 hours. SubQ may cause injection site discomfort. Well-established safety record.

Regulatory & Legal Status

FDA Status (US)

Research Only

WADA Status (2026)

Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Compounded Drug (Rx)

US Compounding: Available via licensed pharmacy Rx

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

Plasma NAD+ after IV is not the same as nuclear SIRT1 activation as a clinical endpoint.
This site will not treat neurodegeneration or aging from an NAD+ page.

Verdict

NAD+ is a coenzyme, not a peptide. IV bars and SubQ vials are not a longevity NDA. Precursors (NR, NMN) are a different exposure. This page is identity and math, not a sirtuin protocol.

Interactions & Contraindications

IV NAD+ infusions can cause facial flushing, nausea, chest tightness at rapid infusion rates - always infuse slowly. PARP inhibitors (cancer drugs: olaparib, rucaparib) compete for NAD+ - do not combine with oncology treatment without oncologist input. Separate timing from alcohol (competes for NAD+ in metabolism).

Synergies & Common Stacks

+ MOTS-c →

Cofactor plus AMPK peptide. Mechanism overlap on paper. Not a mitochondrial-health NDA and not an IV-clinic protocol.

+ Epitalon →

Epitalon telomerase claims are one-lab. NAD+ is PARP substrate chemistry. That is not a synergistic longevity NDA.

NAD+ vs. Glutathione

Canonical comparison: NAD+ vs Glutathione

Attribute	NAD+	Glutathione
Primary Mechanism	NAD+ restoration → mitochondrial fuel	Antioxidant master regulator (GSH)
Cellular Target	Sirtuins, PARP, mitochondrial ETC	Oxidative stress, glutathione peroxidase
Best For	Energy, longevity, DNA repair, alcohol detox	Skin brightening, liver support, oxidative load
Administration	IV, SC injection, oral (NMN/NR precursors)	IV, SC injection, oral (liposomal)
Combined Use	Often co-administered in IV drip protocols	Often co-administered in IV drip protocols

Verdict: NAD+ and Glutathione address complementary aspects of cellular health - NAD+ powers the cell, Glutathione protects it. They are frequently combined in IV wellness protocols for maximum synergy.

Appears in goal guides

Goal guides are maps, not clinic protocols. A mention here is not a treatment plan.

Anti-Aging & Cellular Longevity

Educational map of GH secretagogues, pineal cytogens, and dermal peptides used in longevity folklore. Telomerase and “youthful gene expression” are not a US anti-aging indication.

View Protocol →

Frequently Asked Questions

What is more effective - NAD+ IV or SubQ injection?▼

IV provides 100% bioavailability but requires clinic visits (1-4 hour infusions). SubQ is more convenient for regular home dosing. Both effectively raise intracellular NAD+ levels. IV is preferred for acute high-dose therapy; SubQ for maintenance.

Why do NAD+ levels decline with age?▼

NAD+ declines ~50% between ages 40-60 due to increased consumption by CD38, increased PARP activity from DNA damage accumulation, and decreased synthesis from the salvage pathway. This decline contributes to mitochondrial dysfunction and aging.

References

Cantó C, Auwerx J “"NAD+ metabolism and the control of energy homeostasis".” Cell Metabolism (2011). PMID: 21531334
Canto C, et al. “NAD+ metabolism and the control of energy homeostasis.” Cell Metab (2015). PMID: 26166745
Mills KF, et al. “Chronic NAD+ supplementation extends health span in mice.” Cell Metab (2016). PMID: 28068222

📚 Related Articles

Epitalon: The Science of Telomerase Activation, Khavinson's Legacy, and Longevity Peptides

14 min read • Longevity

Recommended source10% OFF

Get NAD+ from our recommended source - independently tested, COA-verified, USP <85> endotoxin compliant. Use code 4SS6SFTUGB at checkout.

Buy NAD+See all sources →

Affiliate link · Full review

← Back to Peptide Library